Lenalidomide
Back to searchMolecule Structure
Scientific Name
Lenalidomide
Description of the Drug
Lenalidomide is a thalidomide derivative used to treat multiple myeloma and anemia in low to intermediate risk myelodysplastic syndrome.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB00480
http://www.drugbank.ca/drugs/DB00480
Brand Name(s)
Revlimid
Company Owner(s)
Lotus Pharmaceutical Co Ltd Nantou Plant, Apotex Inc, Cipla Ltd, Arrow International Ltd, Celgene Corp, Dr Reddys Laboratories Ltd, Mylan Pharmaceuticals Inc
Mechanism(s) Of Action
Target Name | Target Type | Action Type | Target ChEMBL ID |
---|---|---|---|
CRL4(CRBN) E3 ubiquitin ligase | PROTEIN COMPLEX | INHIBITOR | CHEMBL3833061 |
Clinical Trial(s)
Unichem Links
SureChEMBL | SCHEMBL32978 | |
PharmGKB | PA162363968 | |
Human Metabolome Database | HMDB0014623 | |
DrugBank | DB00480 | |
PubChem: Thomson Pharma | 14847985 | |
PubChem | 216326 | |
Mcule | MCULE-9771679074 | |
LINCS | LSM-6187 | |
Nikkaji | J1.121.689G | |
BindingDB | 65454 | |
EPA CompTox Dashboard | DTXSID8046664 | |
DrugCentral | 3317 | |
ChemicalBook | CB3855432 | |
Guide to Pharmacology | 7331 | |
rxnorm | REVLIMID | LENALIDOMIDE |
PubChem: Drugs of the Future | 12015317 | |
ChEBI | 63791 |